Stockreport

Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Research and Development Expenses : Increased to $35.0 million in Q4 and $114.2 million for the full year, reflecting higher clinical trial activities. General and Ad [Read more]